topotecan episcleral / 3T Ophthalmics - LARVOL DELTA

Retinoblastoma Phase II Expanded Access Clinical Trial (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Targeted Therapy Technologies, LLC | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2024 ➔ Feb 2025

Enrollment open • Trial initiation date • Eye Cancer • Oncology • Retinal Disorders • Retinoblastoma • Solid Tumor

STEP-RB: Topotecan Episcleral Plaque for Treatment of Retinoblastoma (clinicaltrials.gov) - P1 | N=26 | Completed | Sponsor: The Hospital for Sick Children | Recruiting ➔ Completed | Trial completion date: Oct 2030 ➔ Oct 2024 | Trial primary completion date: Oct 2025 ➔ Oct 2024

Trial completion • Trial completion date • Trial primary completion date • Eye Cancer • Oncology • Retinal Disorders • Retinoblastoma • Solid Tumor

Retinoblastoma Phase II Expanded Access Clinical Trial (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Targeted Therapy Technologies, LLC

New P2 trial • Eye Cancer • Oncology • Retinal Disorders • Retinoblastoma • Solid Tumor

Topotecan Episcleral Plaque for Treatment of Retinoblastoma (clinicaltrials.gov) - P1 | N=42 | Active, not recruiting | Sponsor: Targeted Therapy Technologies, LLC | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2023 ➔ Oct 2024 | Trial primary completion date: Oct 2023 ➔ Oct 2024

Enrollment closed • Trial completion date • Trial primary completion date • Eye Cancer • Oncology • Retinal Disorders • Retinoblastoma • Solid Tumor

Topotecan Episcleral Plaque for Treatment of Retinoblastoma (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Targeted Therapy Technologies, LLC | N=30 ➔ 42

Enrollment change • Eye Cancer • Oncology • Retinal Disorders • Retinoblastoma • Solid Tumor

Atypical anterior retinoblastoma: diagnosis by aqueous humor cell-free DNA analysis. (PubMed, Ophthalmic Genet) - "Partial regression followed three cycles of systemic carboplatin, etoposide, and vincristine and three intracameral melphalan injections. Four months later, she had recurrence of the primary tumor and increase in seeding and received the investigational sustained release episcleral topotecan chemoplaque. Stable regression was achieved to 28-month follow-up, with no detectable aqueous cell-free DNA. RB1 sequencing analysis of tumor-derived cell-free DNA from aqueous humor can confirm the diagnosis of retinoblastoma in cases of diagnostic uncertainty."

Journal • Eye Cancer • Immunology • Ocular Inflammation • Oncology • Ophthalmology • Pain • Retinal Disorders • Retinoblastoma • Solid Tumor • Uveitis • RB1

Hydrogel implants for transscleral diffusion delivery of topotecan: In vivo proof of concept in a rabbit eye model. (PubMed, Int J Pharm) - "The determination of TPT pharmacokinetics demonstrates the attainment of promising levels of TPT (10 ng/ml) in vitreous humor 8h after implant placement. The results from the pilot experiment constitute the proof of principle for the use of the proposed implants as a drug delivery system for the local treatment of intraocular diseases."

Journal • Preclinical • Eye Cancer • Oncology • Ophthalmology • Retinal Disorders • Retinoblastoma • Solid Tumor

Topotecan Episcleral Plaque for Treatment of Retinoblastoma (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Targeted Therapy Technologies, LLC; Not yet recruiting ➔ Recruiting; N=12 ➔ 30; Trial completion date: Oct 2021 ➔ Oct 2023; Trial primary completion date: Oct 2021 ➔ Oct 2023

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Eye Cancer • Oncology • Retinal Disorders • Retinoblastoma • Solid Tumor